Your browser is no longer supported. Please, upgrade your browser.
Settings
FTXH First Trust Nasdaq Pharmaceuticals ETF daily Stock Chart
FTXH [NASD]
First Trust Nasdaq Pharmaceuticals ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-0.26%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-1.01%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter0.96%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y0.71%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-8.98%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range17.94 - 23.94 Perf YTD6.82%
Dividend0.13 P/FCF- EPS past 5Y- ROI- 52W High-14.46% Beta-
Dividend %0.63% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low14.15% ATR0.22
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)49.21 Volatility0.22% 0.37%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.14 Prev Close20.52
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.19K Price20.48
Recom- SMA20-0.07% SMA50-1.14% SMA200-2.26% Volume311 Change-0.20%
Aug-07-19 10:59AM  Pharma Q2 Earnings Growth Highest: Time to Buy ETFs? Zacks
May-09-19 10:05AM  Pharma ETFs Down Despite Solid Q1 Results Zacks
Mar-01-19 08:00AM  Why These Pharma ETFs Rallied on Thursday Zacks
Feb-28-19 04:43PM  Pharmaceutical ETFs Break Out on Horizon Pharmas Positive Drug Results ETF Trends
Feb-07-19 11:15AM  A Look at Pharma ETFs Post Q4 Results Zacks
Jan-23-19 02:04PM  Healthcare ETFs Slip After Abbot Labs Revenue Miss, Weak Outlook ETF Trends
Oct-24-18 11:59AM  ETF Strategies for the Midterm Elections Zacks
Oct-12-18 06:00AM  Top 5 Pharmaceutical ETFs for 2018 Investopedia
Jan-26-18 09:02AM  Pfizers 4Q17 Estimates: Products with Lower Sales Market Realist
Jan-12-18 07:31AM  Wall Street Recommendations for Mylan in January 2018 Market Realist
Jan-01-18 07:33AM  Eli Lillys New Products Portfolio in 3Q17 Market Realist
Sep-12-17 10:36AM  Behind Mercks Animal Health Segment Performance in 2Q17 Market Realist
Sep-04-17 09:06AM  What to Expect from Pfizers Biosimilars Business Market Realist
Sep-01-17 07:38AM  Performance of Eli Lillys Business Segments in 2Q17 Market Realist
Aug-30-17 09:07AM  Major Developments for Johnson & Johnson in 2Q17 Market Realist
Aug-11-17 03:59PM  Pfizers Valuation after 2Q17 Earnings Market Realist
May-05-17 09:59AM  Trump Wins Healthcare Vote: ETFs to Watch Zacks
Mar-22-17 05:25PM  First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds Business Wire
Dec-09-16 09:36AM  Johnson & Johnsons Revenue Trend in 3Q16 Market Realist
09:36AM  Johnson & Johnsons Revenue Trend in 3Q16
Oct-25-16 03:04PM  Bristol-Myers Squibbs 3Q16 Estimates: Oncology Segment Market Realist
03:04PM  Bristol-Myers Squibbs 3Q16 Estimates: Oncology Segment
Oct-20-16 08:07AM  The Nasdaq Stock Market® Captures 35 Percent of U.S. ETP Listings and Switches in the Third Quarter of 2016 GlobeNewswire
Oct-14-16 12:04PM  Good News: Johnson & Johnsons 3Q16 Revenues Expected to Rise Market Realist
12:04PM  Good News: Johnson & Johnsons 3Q16 Revenues Expected to Rise
Sep-28-16 09:00AM  This Weeks ETF Launches: First Trust Tries Its Hands at Sectors ETF Database
Sep-27-16 09:00AM  This Weeks ETF Launches: First Trust Tries Its Hands at Sectors
Sep-22-16 01:55PM  7 First Trust Smart Sector ETFs to Diversify, Manage Risk ETF Trends
Sep-21-16 09:12AM  First Trust Launches Seven ETFs Based on Nasdaq US Smart Sector IndexesSM Business Wire
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.